LifeSpan BioSciences to release 20,000 immunohistochemistry-validated reagent antibodies

Leader in antibody evaluation and validation expands focus to include development and sales of antibodies validated for use in immunohistochemistry

13-Jun-2008

lifespan BioSciences, Inc., announced an initiative to release 20,000 immunohistochemistry-validated reagent antibodies over the next four years. The leader in immunohistochemistry (IHC) antibody validation research since 1995, LifeSpan expanded its product focus to include the development and sale of IHC-validated antibodies in Q4 2006. To date, LifeSpan has built a catalog of more than 37,000 reagent antibodies, including more than 2,000 antibodies validated for use in immunohistochemistry. The company intends to expand its IHC-validated reagent antibody catalog at the rate of 5,000 per year.

"We have a tremendous opportunity to leverage our leadership position in antibody validation to become the dominant provider of high-quality antibodies to the research and pharmaceutical communities," said Glenna Burmer, M.D., Ph.D., chief scientific officer and executive vice president of LifeSpan. "This is a very exciting time for LifeSpan. Our experience providing IHC services to over 300 pharmaceutical and biotech companies for the past 12 years positions us as uniquely capable of identifying the best antibodies for future diagnostic and therapeutic applications."

Other news from the department manufacturing

Most read news

More news from our other portals

Fighting cancer: latest developments and advances

See the theme worlds for related content

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

View topic world

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous